Everence Capital Management Inc. Raises Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Everence Capital Management Inc. increased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 36.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,850 shares of the biotechnology company’s stock after purchasing an additional 7,420 shares during the period. Everence Capital Management Inc.’s holdings in Ironwood Pharmaceuticals were worth $115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its position in Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,645 shares during the period. CWM LLC grew its position in Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 2,345 shares during the period. SG Americas Securities LLC acquired a new stake in Ironwood Pharmaceuticals during the first quarter valued at $91,000. GAMMA Investing LLC grew its position in Ironwood Pharmaceuticals by 344.1% during the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 8,156 shares during the period. Finally, EntryPoint Capital LLC grew its position in Ironwood Pharmaceuticals by 517.4% during the first quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 8,874 shares during the period.

Ironwood Pharmaceuticals Trading Down 2.6 %

NASDAQ:IRWD opened at $4.08 on Wednesday. The company has a market cap of $638.64 million, a P/E ratio of -0.60 and a beta of 0.48. Ironwood Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $15.70. The company’s 50-day moving average price is $4.45 and its 200-day moving average price is $5.91.

Analyst Upgrades and Downgrades

Several research firms recently commented on IRWD. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target on the stock. Craig Hallum dropped their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $12.17.

Insiders Place Their Bets

In other news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the sale, the insider now directly owns 284,661 shares in the company, valued at $1,215,502.47. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.